secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001564590-21-043995
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports Q2 2021 net loss $21.5M; cash runway into 2H 2023; NKX101 data by year-end
--------------------------------------------------------------------------------

- Net loss $21.5M ($0.66/share) for Q2 2021; R&D expenses $16.0M, G&A $5.7M.
- Cash, equivalents, restricted cash, and short-term investments $280.3M as of June 30, 2021.
- Initial Phase 1 data for NKX101 (CD33-targeted NK cell therapy) expected by end of 2021.
- NKX019 (CD19-targeted NK) Phase 1 patient dosing expected to start in 2H 2021.
- Collaboration with CRISPR Therapeutics to co-develop two CAR-NK candidates and license CRISPR/Cas9 gene editing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021043995/0001564590-21-043995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021043995/nktx-8k_20210812.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-043995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer